{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:53:39Z","timestamp":1793444019014,"version":"4.5.0"},"reference-count":269,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Cancer Institute, National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA267108"],"award-info":[{"award-number":["1R01CA267108"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Cancer Institute, National Institutes of Health","doi-asserted-by":"publisher","award":["1P01CA278732"],"award-info":[{"award-number":["1P01CA278732"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Sex Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bladder cancer (BC) remains a significant global health concern, with substantial sex and racial disparities in incidence, progression, and outcomes. BC is the sixth most common cancer among males and the seventeenth most common among females worldwide. Over 90% of BC cases are urothelial carcinoma (UC) with high degrees of pathological heterogeneity. Molecular subtyping of BC has also revealed distinct luminal, basal, and neuroendocrine subtypes, each with unique genetic and immune signatures. Emerging research uncovers the biasing effects of the sex hormones with androgens increasing BC risk through both tumor cell intrinsic and extrinsic mechanisms. The sex chromosomes, including both the X and Y chromosomes, also contribute to the sex differences in BC. The effect of sex chromosome is both independent from and synergistic with the effects of sex hormones. Loss of the Y chromosome is frequently observed in BC patients, while an extra copy of the X chromosome confers better protection against BC in females than in males. Advent of advanced technologies such as multiomics and artificial intelligence will likely further improve the understanding of sex differences in BC, which may ultimately lead to personalized preventative and treatment strategies depending on the biological sex of patients. This review delves into the impacts of biology of sex on BC, emphasizing the importance of further research into sex-specific biology to improve cancer prevention and care. <\/jats:p>","DOI":"10.1186\/s13293-025-00715-6","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:35:08Z","timestamp":1747114508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sex differences in bladder cancer: understanding biological and clinical implications"],"prefix":"10.1186","volume":"16","author":[{"given":"Prakash","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"Singha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany A.","family":"Abdel-Hafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Velegraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Satturwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V.","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei I.","family":"Grivennikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Goodridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"6","key":"715_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","volume":"55","author":"NA Mungan","year":"2000","unstructured":"Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh J-WW, Witjes JA, Kiemeney LA. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55(6):876\u201380.","journal-title":"Urology"},{"issue":"1","key":"715_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"715_CR3","doi-asserted-by":"publisher","first-page":"eaar5598","DOI":"10.1126\/sciadv.aar5598","volume":"4","author":"S Kaneko","year":"2018","unstructured":"Kaneko S, Li X. X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci Adv. 2018;4(6):eaar5598. https:\/\/doi.org\/10.1126\/sciadv.aar5598.","journal-title":"Sci Adv"},{"issue":"3","key":"715_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"715_CR5","volume-title":"World cancer report 2014","author":"B Stewart","year":"2014","unstructured":"Stewart B, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014."},{"issue":"2","key":"715_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21(2):104\u201321. https:\/\/doi.org\/10.1038\/s41568-020-00313-1.","journal-title":"Nat Rev Cancer"},{"key":"715_CR7","volume-title":"Urinary and male genital tumours: WHO classification of tumours","author":"H Moch","year":"2022","unstructured":"Moch H. Urinary and male genital tumours: WHO classification of tumours, vol. 8. Lyon: IARC Publications; 2022."},{"issue":"1","key":"715_CR8","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1097\/PAS.0000000000002053","volume":"48","author":"JI Warrick","year":"2024","unstructured":"Warrick JI, Al-Ahmadie H, Berman DM, Black PC, Flaig TW, H\u00f6glund M, et al. International society of urological pathology consensus conference on current issues in bladder cancer. Working group 4: molecular subtypes of bladder cancer\u2014principles of classification and emerging clinical utility. Am J Surg Pathol. 2024;48(1):e32\u201342.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"715_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006.","journal-title":"Eur Urol"},{"issue":"3","key":"715_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540\u201356.e25.","journal-title":"Cell"},{"issue":"9","key":"715_CR11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","volume":"24","author":"P Eriksson","year":"2022","unstructured":"Eriksson P, Bernardo C, Hurst CD, Knowles MA, Sj\u00f6dahl G, Liedberg F, H\u00f6glund M. The lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma. J Mol Diagn. 2022;24(9):992\u20131008.","journal-title":"J Mol Diagn"},{"issue":"12","key":"715_CR12","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377\u201386.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"715_CR13","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","volume":"73","author":"I Kinde","year":"2013","unstructured":"Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Can Res. 2013;73(24):7162\u20137.","journal-title":"Can Res"},{"issue":"34","key":"715_CR14","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353\u201360.","journal-title":"J Clin Oncol"},{"issue":"6","key":"715_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Ross JS, Far\u00e8 E, Giannatempo P, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020;77(6):701\u201310.","journal-title":"Eur Urol"},{"issue":"3","key":"715_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/JU.0000000000002261","volume":"207","author":"Y Lotan","year":"2022","unstructured":"Lotan Y, De Jong JJ, Liu VY, Bismar TA, Boorjian SA, Huang H-C, et al. Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. 2022;207(3):541\u201350.","journal-title":"J Urol"},{"issue":"5","key":"715_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.juro.2018.04.065","volume":"200","author":"WS Tan","year":"2018","unstructured":"Tan WS, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, et al. Can renal and bladder ultrasound replace computerized tomography urogram in patients investigated for microscopic hematuria? J Urol. 2018;200(5):973\u201380. https:\/\/doi.org\/10.1016\/j.juro.2018.04.065.","journal-title":"J Urol"},{"issue":"8","key":"715_CR18","first-page":"507","volume":"96","author":"KC DeGEORGE","year":"2017","unstructured":"DeGEORGE KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician. 2017;96(8):507\u201314.","journal-title":"Am Fam Physician"},{"issue":"4","key":"715_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. Bladder cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2024;22(4):216\u201325.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"715_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1464-410X.2012.11661.x","volume":"112","author":"A Henning","year":"2013","unstructured":"Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Comploj E, et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int. 2013;112(1):68\u201373. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11661.x.","journal-title":"BJU Int"},{"issue":"4","key":"715_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/cncr.28416","volume":"120","author":"JA Cohn","year":"2014","unstructured":"Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer. 2014;120(4):555\u201361.","journal-title":"Cancer"},{"issue":"1","key":"715_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Escrig JLD, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"1","key":"715_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes JA, Bruins HM, Carrion A, Cathomas R, Comperat E, Efstathiou JA, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331.","journal-title":"Eur Urol"},{"issue":"2","key":"715_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192(2):305\u201315.","journal-title":"J Urol"},{"issue":"4","key":"715_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"3","key":"715_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19(3):666\u201375.","journal-title":"J Clin Oncol"},{"issue":"4","key":"715_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","volume":"61","author":"JA Efstathiou","year":"2012","unstructured":"Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705\u201311.","journal-title":"Eur Urol"},{"issue":"4","key":"715_CR28","first-page":"159","volume":"16","author":"D Sundi","year":"2014","unstructured":"Sundi D, Svatek RS, Nielsen ME, Schoenberg MP, Bivalacqua TJ. Extent of pelvic lymph node dissection during radical cystectomy: is bigger better? Rev Urol. 2014;16(4):159.","journal-title":"Rev Urol"},{"issue":"9","key":"715_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights V, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"},{"issue":"21","key":"715_CR30","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"715_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"715_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322.","journal-title":"Lancet Oncol"},{"issue":"10064","key":"715_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67\u201376.","journal-title":"The Lancet"},{"issue":"12","key":"715_CR34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee J-L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"715_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"715_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ucl.2013.01.012","volume":"40","author":"JB Shah","year":"2013","unstructured":"Shah JB, Kamat AM. Strategies for optimizing bacillus Calmette-Guerin. Urol Clin. 2013;40(2):211\u20138.","journal-title":"Urol Clin"},{"issue":"2","key":"715_CR37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"WJ Catalona","year":"1987","unstructured":"Catalona WJ, M\u2019liss AH, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137(2):220\u20134.","journal-title":"J Urol"},{"issue":"1","key":"715_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000273461","volume":"84","author":"M Porena","year":"2010","unstructured":"Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V, Costantini E. Bacillus Calmette-Gu\u00e9rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23\u20137.","journal-title":"Urol Int"},{"issue":"5","key":"715_CR39","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, Meijden AP, van der Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"issue":"6","key":"715_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.11622\/smedj.2020168","volume":"63","author":"X Yang","year":"2022","unstructured":"Yang X, Toh Q, Huang HH, Sng L-H, Tan TT, Ng LG. Intravesical bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution. Singapore Med J. 2022;63(6):325.","journal-title":"Singapore Med J"},{"issue":"6","key":"715_CR41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.eururo.2010.02.024","volume":"57","author":"N Lawrentschuk","year":"2010","unstructured":"Lawrentschuk N, Colombo R, Hakenberg OW, Lerner SP, M\u00e5nsson W, Sagalowsky A, Wirth MP. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010;57(6):983\u20131001.","journal-title":"Eur Urol"},{"issue":"6","key":"715_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10552-023-01679-x","volume":"34","author":"TD Shu","year":"2023","unstructured":"Shu TD, Schumacher FR, Conroy B, Ponsky L, Mahran A, Bukavina L, et al. Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database. Cancer Causes Control. 2023;34(6):521\u201331.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"715_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.23986","volume":"115","author":"E Scosyrev","year":"2009","unstructured":"Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68\u201374.","journal-title":"Cancer"},{"issue":"1","key":"715_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41389-023-00489-9","volume":"12","author":"B Doshi","year":"2023","unstructured":"Doshi B, Athans SR, Woloszynska A. Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions. Oncogenesis. 2023;12(1):44.","journal-title":"Oncogenesis"},{"issue":"10","key":"715_CR45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41568-024-00725-3","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li X. The impact of sex on metastasis. Nat Rev Cancer. 2024;24(10):647\u20138. https:\/\/doi.org\/10.1038\/s41568-024-00725-3.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"715_CR46","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/jjco\/hyaa273","volume":"51","author":"G Rosiello","year":"2021","unstructured":"Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, et al. Sex- and age-related differences in the distribution of bladder cancer metastases. Jpn J Clin Oncol. 2021;51(6):976\u201383. https:\/\/doi.org\/10.1093\/jjco\/hyaa273.","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"715_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107703","volume":"26","author":"HA Abdel-Hafiz","year":"2023","unstructured":"Abdel-Hafiz HA, Kailasam Mani SK, Huang W, Gouin KH III, Chang Y, Xiao T, et al. Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance. iScience. 2023;26(9): 107703. https:\/\/doi.org\/10.1016\/j.isci.2023.107703.","journal-title":"iScience"},{"issue":"20","key":"715_CR48","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/jnci\/82.20.1636","volume":"82","author":"P Hartge","year":"1990","unstructured":"Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF Jr. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82(20):1636\u201340. https:\/\/doi.org\/10.1093\/jnci\/82.20.1636.","journal-title":"J Natl Cancer Inst"},{"issue":"7915","key":"715_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41586-022-04833-8","volume":"606","author":"CP Vellano","year":"2022","unstructured":"Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, et al. Androgen receptor blockade promotes response to BRAF\/MEK-targeted therapy. Nature. 2022;606(7915):797\u2013803. https:\/\/doi.org\/10.1038\/s41586-022-04833-8.","journal-title":"Nature"},{"issue":"473","key":"715_CR50","doi-asserted-by":"publisher","first-page":"eaao5253","DOI":"10.1126\/scitranslmed.aao5253","volume":"11","author":"W Yang","year":"2019","unstructured":"Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, Singleton KW, et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med. 2019;11(473):eaao5253. https:\/\/doi.org\/10.1126\/scitranslmed.aao5253.","journal-title":"Sci Transl Med"},{"issue":"1","key":"715_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euf.2014.11.001","volume":"1","author":"M Rink","year":"2015","unstructured":"Rink M, Crivelli JJ, Shariat SF, Chun FK, Messing EM, Soloway MS. Smoking and bladder cancer: a systematic review of risk and outcomes. Eur Urol Focus. 2015;1(1):17\u201327.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"715_CR52","first-page":"279","volume":"34","author":"NN Kamal","year":"2023","unstructured":"Kamal NN, Mahmoud AMEA, Khalifa MAZ, Mohammed KH, Hassan EE. Association between smoking and urinary bladder cancer (BC): case control study in Minia, Egypt. Minia J Med Res. 2023;34(1):279\u201388.","journal-title":"Minia J Med Res"},{"issue":"5","key":"715_CR53","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/MOU.0000000000000804","volume":"30","author":"K Mori","year":"2020","unstructured":"Mori K, Mostafaei H, Abufaraj M, Yang L, Egawa S, Shariat SF. Smoking and bladder cancer: review of the recent literature. Curr Opin Urol. 2020;30(5):720\u20135.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"715_CR54","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.juro.2013.01.024","volume":"189","author":"M Hagiwara","year":"2013","unstructured":"Hagiwara M, Kikuchi E, Tanaka N, Matsumoto K, Ide H, Miyajima A, et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2013;189(6):2062\u20138.","journal-title":"J Urol"},{"issue":"1","key":"715_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11255-016-1441-6","volume":"49","author":"HM Li","year":"2017","unstructured":"Li HM, Azhati B, Rexiati M, Wang WG, Li XD, Liu Q, Wang YJ. Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer. Int Urol Nephrol. 2017;49(1):69\u201376. https:\/\/doi.org\/10.1007\/s11255-016-1441-6.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"715_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/SLA.0b013e3182911913","volume":"259","author":"M Gronkjaer","year":"2014","unstructured":"Gronkjaer M, Eliasen M, Skov-Ettrup LS, Tolstrup JS, Christiansen AH, Mikkelsen SS, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. Ann Surg. 2014;259(1):52\u201371. https:\/\/doi.org\/10.1097\/SLA.0b013e3182911913.","journal-title":"Ann Surg"},{"key":"715_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00423-006-0111-z","volume":"391","author":"SS Hecht","year":"2006","unstructured":"Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006;391:603\u201313.","journal-title":"Langenbecks Arch Surg"},{"issue":"10","key":"715_CR58","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/carcin\/23.10.1721","volume":"23","author":"Z Feng","year":"2002","unstructured":"Feng Z, Hu W, Rom WN, Beland FA, Tang M. 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis. 2002;23(10):1721\u20137.","journal-title":"Carcinogenesis"},{"key":"715_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2015.10.018","volume":"52","author":"V Yu","year":"2016","unstructured":"Yu V, Rahimy M, Korrapati A, Xuan Y, Zou AE, Krishnan AR, et al. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol. 2016;52:58\u201365.","journal-title":"Oral Oncol"},{"issue":"5","key":"715_CR60","first-page":"321","volume":"6","author":"Z-F Zhang","year":"1997","unstructured":"Zhang Z-F, Shu X-M, Cordon-Cardo C, Orlow I, Lu M-L, Millon TV, et al. Cigarette smoking and chromosome 9 alterations in bladder cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(5):321\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"43","key":"715_CR61","doi-asserted-by":"publisher","first-page":"21727","DOI":"10.1073\/pnas.1911321116","volume":"116","author":"MS Tang","year":"2019","unstructured":"Tang MS, Wu XR, Lee HW, Xia Y, Deng FM, Moreira AL, et al. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proc Natl Acad Sci U S A. 2019;116(43):21727\u201331. https:\/\/doi.org\/10.1073\/pnas.1911321116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"715_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1019199","volume":"4","author":"JM Clement","year":"2015","unstructured":"Clement JM, Duan F, Srivastava PK. Smoking-induced immune deviation contributes to progression of bladder and other cancers. Oncoimmunology. 2015;4(9): e1019199. https:\/\/doi.org\/10.1080\/2162402X.2015.1019199.","journal-title":"Oncoimmunology"},{"issue":"6","key":"715_CR63","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.001.","journal-title":"Eur Urol"},{"issue":"11","key":"715_CR64","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/jnci\/djy045","volume":"110","author":"S Koutros","year":"2018","unstructured":"Koutros S, Lenz P, Hewitt SM, Kida M, Jones M, Schned AR, et al. RE: Elevated bladder cancer in northern New England: the role of drinking water and arsenic. J Natl Cancer Inst. 2018;110(11):1273\u20134. https:\/\/doi.org\/10.1093\/jnci\/djy045.","journal-title":"J Natl Cancer Inst"},{"issue":"9486","key":"715_CR65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0140-6736(05)67137-1","volume":"366","author":"M Garcia-Closas","year":"2005","unstructured":"Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(05)67137-1.","journal-title":"Lancet"},{"issue":"2","key":"715_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/jcm10020205","volume":"10","author":"LL Santos","year":"2021","unstructured":"Santos LL, Santos J, Gouveia MJ, Bernardo C, Lopes C, Rinaldi G, et al. Urogenital schistosomiasis-history, pathogenesis, and bladder cancer. J Clin Med. 2021;10(2):205. https:\/\/doi.org\/10.3390\/jcm10020205.","journal-title":"J Clin Med"},{"issue":"3","key":"715_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002605","volume":"8","author":"CL Fu","year":"2012","unstructured":"Fu CL, Odegaard JI, Herbert DR, Hsieh MH. A novel mouse model of Schistosoma haematobium egg-induced immunopathology. PLoS Pathog. 2012;8(3): e1002605. https:\/\/doi.org\/10.1371\/journal.ppat.1002605.","journal-title":"PLoS Pathog"},{"issue":"1","key":"715_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40794-022-00161-x","volume":"8","author":"B Efared","year":"2022","unstructured":"Efared B, Bako ABA, Idrissa B, Alhousseini D, Boureima HS, Sode HC, Nouhou H. Urinary bladder Schistosoma haematobium-related squamous cell carcinoma: a report of two fatal cases and literature review. Trop Dis Travel Med Vaccines. 2022;8(1):3. https:\/\/doi.org\/10.1186\/s40794-022-00161-x.","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"5","key":"715_CR69","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.juro.2017.06.083","volume":"198","author":"JT Ark","year":"2017","unstructured":"Ark JT, Alvarez JR, Koyama T, Bassett JC, Blot WJ, Mumma MT, et al. Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race and risk factors for bladder cancer. J Urol. 2017;198(5):1033\u20138.","journal-title":"J Urol"},{"issue":"3","key":"715_CR70","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.urology.2008.01.086","volume":"72","author":"EK Johnson","year":"2008","unstructured":"Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498\u2013502.","journal-title":"Urology"},{"issue":"4","key":"715_CR71","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.juro.2014.04.101","volume":"192","author":"T Garg","year":"2014","unstructured":"Garg T, Pinheiro LC, Atoria CL, Donat SM, Weissman JS, Herr HW, Elkin EB. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol. 2014;192(4):1072\u20137.","journal-title":"J Urol"},{"issue":"1","key":"715_CR72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000363334","volume":"94","author":"A Aziz","year":"2015","unstructured":"Aziz A, Madersbacher S, Otto W, Mayr R, Comploj E, Pycha A, et al. Comparative analysis of gender-related differences in symptoms and referral patterns prior to initial diagnosis of urothelial carcinoma of the bladder: a prospective cohort study. Urol Int. 2015;94(1):37\u201344.","journal-title":"Urol Int"},{"issue":"6","key":"715_CR73","first-page":"1045","volume":"98","author":"JS Brown","year":"2001","unstructured":"Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol. 2001;98(6):1045\u201352.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"715_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/19338244.2013.853646","volume":"70","author":"S Amr","year":"2015","unstructured":"Amr S, Dawson R, Saleh DA, Magder LS, St George DM, El-Daly M, et al. Pesticides, gene polymorphisms, and bladder cancer among Egyptian agricultural workers. Arch Environ Occup Health. 2015;70(1):19\u201326.","journal-title":"Arch Environ Occup Health"},{"issue":"2","key":"715_CR75","first-page":"158","volume":"19","author":"I Gouda","year":"2007","unstructured":"Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst. 2007;19(2):158\u201362.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"3","key":"715_CR76","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/bjc.2014.601","volume":"112","author":"SH Vermeulen","year":"2015","unstructured":"Vermeulen SH, Hanum N, Grotenhuis AJ, Castano-Vinyals G, Van Der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112(3):594\u2013600.","journal-title":"Br J Cancer"},{"key":"715_CR77","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00345-018-2206-x","volume":"36","author":"S Akhtar","year":"2018","unstructured":"Akhtar S, Al-Shammari A, Al-Abkal J. Chronic urinary tract infection and bladder carcinoma risk: a meta-analysis of case\u2013control and cohort studies. World J Urol. 2018;36:839\u201348.","journal-title":"World J Urol"},{"issue":"1","key":"715_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/tcmj.tcmj_38_20","volume":"33","author":"Q-S Ke","year":"2021","unstructured":"Ke Q-S, Lee C-L, Kuo H-C. Recurrent urinary tract infection in women and overactive bladder\u2014is there a relationship? Tzu Chi Med J. 2021;33(1):13\u201321.","journal-title":"Tzu Chi Med J"},{"issue":"3","key":"715_CR79","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"715_CR80","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tem.2020.01.010","volume":"31","author":"J Kroon","year":"2020","unstructured":"Kroon J, Pereira AM, Meijer OC. Glucocorticoid sexual dimorphism in metabolism: dissecting the role of sex hormones. Trends Endocrinol Metab. 2020;31(5):357\u201367. https:\/\/doi.org\/10.1016\/j.tem.2020.01.010.","journal-title":"Trends Endocrinol Metab"},{"issue":"26","key":"715_CR81","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1200\/JCO.2009.27.4290","volume":"28","author":"EJ Folkerd","year":"2010","unstructured":"Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol. 2010;28(26):4038\u201344. https:\/\/doi.org\/10.1200\/JCO.2009.27.4290.","journal-title":"J Clin Oncol"},{"issue":"1","key":"715_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cll.2004.01.004","volume":"24","author":"JP Holst","year":"2004","unstructured":"Holst JP, Soldin OP, Guo T, Soldin SJ. Steroid hormones: relevance and measurement in the clinical laboratory. Clin Lab Med. 2004;24(1):105\u201318.","journal-title":"Clin Lab Med"},{"issue":"1","key":"715_CR83","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1530\/JME-14-0203","volume":"54","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol. 2015;54(1):R15\u201329.","journal-title":"J Mol Endocrinol"},{"key":"715_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/1477-3163.83937","volume":"10","author":"PE Lonergan","year":"2011","unstructured":"Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20.","journal-title":"J Carcinog"},{"issue":"6","key":"715_CR85","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/0014-2964(72)90137-5","volume":"8","author":"JS Bertram","year":"1972","unstructured":"Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8(6):587\u201394. https:\/\/doi.org\/10.1016\/0014-2964(72)90137-5.","journal-title":"Eur J Cancer"},{"issue":"2","key":"715_CR86","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00256185","volume":"3","author":"E Okajima","year":"1975","unstructured":"Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res. 1975;3(2):73\u20139. https:\/\/doi.org\/10.1007\/BF00256185.","journal-title":"Urol Res"},{"issue":"4","key":"715_CR87","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.juro.2018.04.082","volume":"200","author":"VJ Makela","year":"2018","unstructured":"Makela VJ, Kotsar A, Tammela TLJ, Murtola TJ. Bladder cancer survival of men receiving 5alpha-reductase inhibitors. J Urol. 2018;200(4):743\u20138. https:\/\/doi.org\/10.1016\/j.juro.2018.04.082.","journal-title":"J Urol"},{"issue":"2","key":"715_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0090-4295(85)90534-5","volume":"25","author":"E Laor","year":"1985","unstructured":"Laor E, Schiffman ZJ, Braunstein JD, Reid RE, Tolia BM, Koss LG, Freed SZ. Androgen receptors in bladder tumors. Urology. 1985;25(2):161\u20133. https:\/\/doi.org\/10.1016\/0090-4295(85)90534-5.","journal-title":"Urology"},{"issue":"6","key":"715_CR89","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00006324-198006000-00004","volume":"57","author":"BW Wild","year":"1980","unstructured":"Wild BW. Symposium on health manpower credentialing: the optometric view. Am J Optom Physiol Opt. 1980;57(6):344\u20139.","journal-title":"Am J Optom Physiol Opt"},{"issue":"5","key":"715_CR90","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ajpath.2013.01.018","volume":"182","author":"JW Hsu","year":"2013","unstructured":"Hsu JW, Hsu I, Xu D, Miyamoto H, Liang L, Wu XR, et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013;182(5):1811\u201320. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.018.","journal-title":"Am J Pathol"},{"issue":"2","key":"715_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148851","volume":"11","author":"DT Johnson","year":"2016","unstructured":"Johnson DT, Hooker E, Luong R, Yu EJ, He Y, Gonzalgo ML, Sun Z. Conditional expression of the androgen receptor increases susceptibility of bladder cancer in mice. PLoS ONE. 2016;11(2): e0148851. https:\/\/doi.org\/10.1371\/journal.pone.0148851.","journal-title":"PLoS ONE"},{"issue":"7","key":"715_CR92","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/jnci\/djk113","volume":"99","author":"H Miyamoto","year":"2007","unstructured":"Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558\u201368. https:\/\/doi.org\/10.1093\/jnci\/djk113.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"715_CR93","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41419-023-05882-1","volume":"14","author":"L Yang","year":"2023","unstructured":"Yang L, Huang W, Bai X, Wang H, Wang X, Xiao H, Li Y. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK\/JUP signalling. Cell Death Dis. 2023;14(6):363. https:\/\/doi.org\/10.1038\/s41419-023-05882-1.","journal-title":"Cell Death Dis"},{"issue":"3","key":"715_CR94","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41388-019-0964-6","volume":"39","author":"J Chen","year":"2020","unstructured":"Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, et al. Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Galphai protein\/MAPK\/MMP9 intracellular signaling. Oncogene. 2020;39(3):574\u201386. https:\/\/doi.org\/10.1038\/s41388-019-0964-6.","journal-title":"Oncogene"},{"issue":"51","key":"715_CR95","doi-asserted-by":"publisher","first-page":"E3588","DOI":"10.1073\/pnas.1113960109","volume":"109","author":"JB Overdevest","year":"2012","unstructured":"Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci USA. 2012;109(51):E3588\u201396. https:\/\/doi.org\/10.1073\/pnas.1113960109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"715_CR96","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-20-3095","volume":"81","author":"JL Sottnik","year":"2021","unstructured":"Sottnik JL, Vanderlinden L, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, et al. Androgen receptor regulates CD44 expression in bladder cancer. Cancer Res. 2021;81(11):2833\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3095.","journal-title":"Cancer Res"},{"issue":"14","key":"715_CR97","doi-asserted-by":"publisher","first-page":"14691","DOI":"10.18632\/aging.103523","volume":"12","author":"X Xu","year":"2020","unstructured":"Xu X, Mo Q, Shen H, Wang S, Liu B. Reproductive and hormonal factors and bladder cancer risk: a prospective study and meta-analysis. Aging. 2020;12(14):14691\u20138. https:\/\/doi.org\/10.18632\/aging.103523.","journal-title":"Aging"},{"issue":"10","key":"715_CR98","first-page":"4560","volume":"44","author":"LM Reid","year":"1984","unstructured":"Reid LM, Leav I, Kwan PW, Russell P, Merk FB. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res. 1984;44(10):4560\u201373.","journal-title":"Cancer Res"},{"issue":"3","key":"715_CR99","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s0302-2838(02)00038-6","volume":"41","author":"A Basakci","year":"2002","unstructured":"Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol. 2002;41(3):342\u20135. https:\/\/doi.org\/10.1016\/s0302-2838(02)00038-6.","journal-title":"Eur Urol"},{"issue":"1\u20132","key":"715_CR100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s0303-7207(00)00233-1","volume":"164","author":"S Makela","year":"2000","unstructured":"Makela S, Strauss L, Kuiper G, Valve E, Salmi S, Santti R, Gustafsson JA. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol. 2000;164(1\u20132):109\u201316. https:\/\/doi.org\/10.1016\/s0303-7207(00)00233-1.","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"715_CR101","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41419-019-1827-3","volume":"10","author":"L Wu","year":"2019","unstructured":"Wu L, Zhang M, Qi L, Zu X, Li Y, Liu L, et al. ER\u03b1-mediated alterations in circ_0023642 and miR-490-5p signaling suppress bladder cancer invasion. Cell Death Dis. 2019;10(9):635. https:\/\/doi.org\/10.1038\/s41419-019-1827-3.","journal-title":"Cell Death Dis"},{"issue":"11","key":"715_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0155-5","volume":"50","author":"Z Ou","year":"2018","unstructured":"Ou Z, Wang Y, Chen J, Tao L, Zuo L, Sahasrabudhe D, et al. Estrogen receptor \u03b2 promotes bladder cancer growth and invasion via alteration of miR-92a\/DAB2IP signals. Exp Mol Med. 2018;50(11):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0155-5.","journal-title":"Exp Mol Med"},{"issue":"17","key":"715_CR103","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.18632\/oncotarget.1421","volume":"5","author":"I Hsu","year":"2014","unstructured":"Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, et al. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 2014;5(17):7917\u201335. https:\/\/doi.org\/10.18632\/oncotarget.1421.","journal-title":"Oncotarget"},{"issue":"6","key":"715_CR104","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrurol.2013.53","volume":"10","author":"I Hsu","year":"2013","unstructured":"Hsu I, Vitkus S, Da J, Yeh S. Role of oestrogen receptors in bladder cancer development. Nat Rev Urol. 2013;10(6):317\u201326. https:\/\/doi.org\/10.1038\/nrurol.2013.53.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"715_CR105","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1593\/tlo.13247","volume":"6","author":"SK George","year":"2013","unstructured":"George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol. 2013;6(3):244\u201355. https:\/\/doi.org\/10.1593\/tlo.13247.","journal-title":"Transl Oncol"},{"issue":"7","key":"715_CR106","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41574-023-00822-7","volume":"19","author":"ER Prossnitz","year":"2023","unstructured":"Prossnitz ER, Barton M. The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nat Rev Endocrinol. 2023;19(7):407\u201324. https:\/\/doi.org\/10.1038\/s41574-023-00822-7.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"715_CR107","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1210\/en.2007-1669","volume":"149","author":"J Teng","year":"2008","unstructured":"Teng J, Wang ZY, Prossnitz ER, Bjorling DE. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology. 2008;149(8):4024\u201334. https:\/\/doi.org\/10.1210\/en.2007-1669.","journal-title":"Endocrinology"},{"key":"715_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.579420","volume":"11","author":"G Notas","year":"2020","unstructured":"Notas G, Kampa M, Castanas E. G protein-coupled estrogen receptor in immune cells and its role in immune-related diseases. Front Endocrinol. 2020;11: 579420. https:\/\/doi.org\/10.3389\/fendo.2020.579420.","journal-title":"Front Endocrinol"},{"key":"715_CR109","doi-asserted-by":"publisher","unstructured":"DeMayo FJ, Zhao B, Takamoto N, Tsai SY. Mechanisms of action of estrogen and progesterone. Ann N Y Acad Sci 2002;955:48\u201359; discussion 86\u20138, 396\u2013406. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb02765.x.","DOI":"10.1111\/j.1749-6632.2002.tb02765.x"},{"issue":"41","key":"715_CR110","doi-asserted-by":"publisher","first-page":"39261","DOI":"10.1074\/jbc.R300024200","volume":"278","author":"X Li","year":"2003","unstructured":"Li X, O\u2019Malley BW. Unfolding the action of progesterone receptors. J Biol Chem. 2003;278(41):39261\u20134. https:\/\/doi.org\/10.1074\/jbc.R300024200.","journal-title":"J Biol Chem"},{"issue":"2","key":"715_CR111","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/humupd\/dmu056","volume":"21","author":"B Patel","year":"2015","unstructured":"Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21(2):155\u201373. https:\/\/doi.org\/10.1093\/humupd\/dmu056.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"715_CR112","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jcp.20962","volume":"211","author":"EJ Chien","year":"2007","unstructured":"Chien EJ, Liao CF, Chang CP, Pu HF, Lu LM, Shie MC, et al. The non-genomic effects on Na+\/H+-exchange 1 by progesterone and 20\u03b1-hydroxyprogesterone in human T cells. J Cell Physiol. 2007;211(2):544\u201350. https:\/\/doi.org\/10.1002\/jcp.20962.","journal-title":"J Cell Physiol"},{"issue":"7560","key":"715_CR113","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ER\u03b1 action in breast cancer. Nature. 2015;523(7560):313\u20137. https:\/\/doi.org\/10.1038\/nature14583.","journal-title":"Nature"},{"issue":"3","key":"715_CR114","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.urology.2008.04.028","volume":"72","author":"AM Johnson","year":"2008","unstructured":"Johnson AM, O\u2019Connell MJ, Messing EM, Reeder JE. Decreased bladder cancer growth in parous mice. Urology. 2008;72(3):470\u20133. https:\/\/doi.org\/10.1016\/j.urology.2008.04.028.","journal-title":"Urology"},{"issue":"9","key":"715_CR115","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/jpm13091418","volume":"13","author":"A Peteinaris","year":"2023","unstructured":"Peteinaris A, Perros P, Prokopakis I, Fasoulakis Z, Ntounis T, Daglas K, et al. Bladder cancer during pregnancy: a review of the literature. J Pers Med. 2023;13(9):1418. https:\/\/doi.org\/10.3390\/jpm13091418.","journal-title":"J Pers Med"},{"issue":"73","key":"715_CR116","doi-asserted-by":"publisher","first-page":"eabq2630","DOI":"10.1126\/sciimmunol.abq2630","volume":"7","author":"H Kwon","year":"2022","unstructured":"Kwon H, Schafer JM, Song N-J, Kaneko S, Li A, Xiao T, et al. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. 2022;7(73):eabq2630.","journal-title":"Sci Immunol"},{"issue":"7970","key":"715_CR117","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","volume":"619","author":"HA Abdel-Hafiz","year":"2023","unstructured":"Abdel-Hafiz HA, Schafer JM, Chen X, Xiao T, Gauntner TD, Li Z, Theodorescu D. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature. 2023;619(7970):624\u201331.","journal-title":"Nature"},{"issue":"3","key":"715_CR118","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(08)70033-0","volume":"9","author":"MJ Schoemaker","year":"2008","unstructured":"Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA, UK Clinical Cytogenetics Group. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(08)70033-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"715_CR119","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ijc.30126","volume":"139","author":"J Ji","year":"2016","unstructured":"Ji J, Zoller B, Sundquist J, Sundquist K. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int J Cancer. 2016;139(4):754\u20138. https:\/\/doi.org\/10.1002\/ijc.30126.","journal-title":"Int J Cancer"},{"key":"715_CR120","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13293-016-0115-5","volume":"7","author":"PS Burgoyne","year":"2016","unstructured":"Burgoyne PS, Arnold AP. A primer on the use of mouse models for identifying direct sex chromosome effects that cause sex differences in non-gonadal tissues. Biol Sex Differ. 2016;7:68. https:\/\/doi.org\/10.1186\/s13293-016-0115-5.","journal-title":"Biol Sex Differ"},{"key":"715_CR121","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pmedr.2018.06.010","volume":"11","author":"C Bruder","year":"2018","unstructured":"Bruder C, Bulliard JL, Germann S, Konzelmann I, Bochud M, Leyvraz M, Chiolero A. Estimating lifetime and 10-year risk of lung cancer. Prev Med Rep. 2018;11:125\u201330. https:\/\/doi.org\/10.1016\/j.pmedr.2018.06.010.","journal-title":"Prev Med Rep"},{"issue":"1","key":"715_CR122","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12885-018-4786-7","volume":"18","author":"A White","year":"2018","unstructured":"White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018;18(1):906. https:\/\/doi.org\/10.1186\/s12885-018-4786-7.","journal-title":"BMC Cancer"},{"issue":"6","key":"715_CR123","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat Rev Cancer. 2021;21(6):393\u2013407. https:\/\/doi.org\/10.1038\/s41568-021-00348-y.","journal-title":"Nat Rev Cancer"},{"key":"715_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.632719","volume":"12","author":"S Haupt","year":"2021","unstructured":"Haupt S, Haupt Y. Cancer and tumour suppressor p53 encounters at the juncture of sex disparity. Front Genet. 2021;12: 632719. https:\/\/doi.org\/10.3389\/fgene.2021.632719.","journal-title":"Front Genet"},{"issue":"7031","key":"715_CR125","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature03479","volume":"434","author":"L Carrel","year":"2005","unstructured":"Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434(7031):400\u20134. https:\/\/doi.org\/10.1038\/nature03479.","journal-title":"Nature"},{"issue":"1","key":"715_CR126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ng.3726","volume":"49","author":"A Dunford","year":"2017","unstructured":"Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017;49(1):10\u20136. https:\/\/doi.org\/10.1038\/ng.3726.","journal-title":"Nat Genet"},{"issue":"1","key":"715_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/rmb2.12445","volume":"21","author":"M Fukami","year":"2022","unstructured":"Fukami M, Miyado M. Mosaic loss of the Y chromosome and men\u2019s health. Reprod Med Biol. 2022;21(1): e12445. https:\/\/doi.org\/10.1002\/rmb2.12445.","journal-title":"Reprod Med Biol"},{"issue":"6","key":"715_CR128","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/ng.2966","volume":"46","author":"LA Forsberg","year":"2014","unstructured":"Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46(6):624\u20138. https:\/\/doi.org\/10.1038\/ng.2966.","journal-title":"Nat Genet"},{"issue":"7784","key":"715_CR129","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-019-1765-3","volume":"575","author":"DJ Thompson","year":"2019","unstructured":"Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature. 2019;575(7784):652\u20137. https:\/\/doi.org\/10.1038\/s41586-019-1765-3.","journal-title":"Nature"},{"issue":"8","key":"715_CR130","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"issue":"6","key":"715_CR131","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1101\/gr.261248.120","volume":"30","author":"AK Godfrey","year":"2020","unstructured":"Godfrey AK, Naqvi S, Chmatal L, Chick JM, Mitchell RN, Gygi SP, et al. Quantitative analysis of Y-chromosome gene expression across 36 human tissues. Genome Res. 2020;30(6):860\u201373. https:\/\/doi.org\/10.1101\/gr.261248.120.","journal-title":"Genome Res"},{"issue":"7","key":"715_CR132","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1172\/JCI96769","volume":"128","author":"K Komura","year":"2018","unstructured":"Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, et al. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018;128(7):2979\u201395. https:\/\/doi.org\/10.1172\/JCI96769.","journal-title":"J Clin Invest"},{"issue":"22","key":"715_CR133","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1073\/pnas.1600420113","volume":"113","author":"K Komura","year":"2016","unstructured":"Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci USA. 2016;113(22):6259\u201364. https:\/\/doi.org\/10.1073\/pnas.1600420113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"715_CR134","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41588-018-0267-9","volume":"51","author":"LA Forsberg","year":"2019","unstructured":"Forsberg LA, Halvardson J, Rychlicka-Buniowska E, Danielsson M, Moghadam BT, Mattisson J, et al. Mosaic loss of chromosome Y in leukocytes matters. Nat Genet. 2019;51(1):4\u20137. https:\/\/doi.org\/10.1038\/s41588-018-0267-9.","journal-title":"Nat Genet"},{"issue":"1","key":"715_CR135","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12864-024-10168-7","volume":"25","author":"J Mattisson","year":"2024","unstructured":"Mattisson J, Halvardson J, Davies H, Bruhn-Olszewska B, Olszewski P, Danielsson M, et al. Loss of chromosome Y in regulatory T cells. BMC Genomics. 2024;25(1):243. https:\/\/doi.org\/10.1186\/s12864-024-10168-7.","journal-title":"BMC Genomics"},{"issue":"5","key":"715_CR136","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00439-017-1799-2","volume":"136","author":"LA Forsberg","year":"2017","unstructured":"Forsberg LA. Loss of chromosome Y (LOY) in blood cells is associated with increased risk for disease and mortality in aging men. Hum Genet. 2017;136(5):657\u201363. https:\/\/doi.org\/10.1007\/s00439-017-1799-2.","journal-title":"Hum Genet"},{"issue":"3","key":"715_CR137","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540\u201356.e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007.","journal-title":"Cell"},{"issue":"7492","key":"715_CR138","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322. https:\/\/doi.org\/10.1038\/nature12965.","journal-title":"Nature"},{"issue":"12","key":"715_CR139","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11934-018-0861-5","volume":"19","author":"SP Porten","year":"2018","unstructured":"Porten SP. Epigenetic alterations in bladder cancer. Curr Urol Rep. 2018;19(12):102.","journal-title":"Curr Urol Rep"},{"issue":"17","key":"715_CR140","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-10-2659","volume":"17","author":"T Reinert","year":"2011","unstructured":"Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011;17(17):5582\u201392.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"715_CR141","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/1078-0432.CCR-09-2983","volume":"16","author":"CS Wilhelm","year":"2010","unstructured":"Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res. 2010;16(5):1682\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"715_CR142","first-page":"143","volume":"15","author":"P Whongsiri","year":"2018","unstructured":"Whongsiri P, Pimratana C, Wijitsettakul U, Jindatip D, Sanpavat A, Schulz WA, et al. LINE-1 ORF1 protein is up-regulated by reactive oxygen species and associated with bladder urothelial carcinoma progression. Cancer Genomics Proteomics. 2018;15(2):143\u201351.","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"715_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000917","volume":"6","author":"EM Wolff","year":"2010","unstructured":"Wolff EM, Byun H-M, Han HF, Sharma S, Nichols PW, Siegmund KD, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010;6(4): e1000917.","journal-title":"PLoS Genet"},{"issue":"5","key":"715_CR144","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","volume":"29","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29(5):711\u201322.","journal-title":"Cancer Cell"},{"issue":"8","key":"715_CR145","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","volume":"26","author":"K Kobatake","year":"2020","unstructured":"Kobatake K, Ikeda KI, Nakata Y, Yamasaki N, Ueda T, Kanai A, et al. Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction. Clin Cancer Res. 2020;26(8):2065\u201379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2230.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"715_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002964","volume":"8","author":"KB Shpargel","year":"2012","unstructured":"Shpargel KB, Sengoku T, Yokoyama S, Magnuson T. UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. PLoS Genet. 2012;8(9): e1002964. https:\/\/doi.org\/10.1371\/journal.pgen.1002964.","journal-title":"PLoS Genet"},{"issue":"32","key":"715_CR147","doi-asserted-by":"publisher","first-page":"13004","DOI":"10.1073\/pnas.1210787109","volume":"109","author":"GG Welstead","year":"2012","unstructured":"Welstead GG, Creyghton MP, Bilodeau S, Cheng AW, Markoulaki S, Young RA, Jaenisch R. X-linked H3K27me3 demethylase Utx is required for embryonic development in a sex-specific manner. Proc Natl Acad Sci USA. 2012;109(32):13004\u20139. https:\/\/doi.org\/10.1073\/pnas.1210787109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"715_CR148","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1242\/dev.143958","volume":"144","author":"C Guo","year":"2017","unstructured":"Guo C, Balsara ZR, Hill WG, Li X. Stage- and subunit-specific functions of polycomb repressive complex 2 in bladder urothelial formation and regeneration. Development. 2017;144(3):400\u20138. https:\/\/doi.org\/10.1242\/dev.143958.","journal-title":"Development"},{"issue":"5","key":"715_CR149","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE, et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell. 2017;32(5):701\u201315.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.005.","journal-title":"Cancer Cell"},{"issue":"5","key":"715_CR150","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cancergen.2015.01.005","volume":"208","author":"DJ Ford","year":"2015","unstructured":"Ford DJ, Dingwall AK. The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genet. 2015;208(5):178\u201391. https:\/\/doi.org\/10.1016\/j.cancergen.2015.01.005.","journal-title":"Cancer Genet"},{"issue":"6290","key":"715_CR151","doi-asserted-by":"publisher","first-page":"aad9780","DOI":"10.1126\/science.aad9780","volume":"352","author":"A Piunti","year":"2016","unstructured":"Piunti A, Shilatifard A. Epigenetic balance of gene expression by polycomb and COMPASS families. Science. 2016;352(6290):aad9780. https:\/\/doi.org\/10.1126\/science.aad9780.","journal-title":"Science"},{"issue":"10","key":"715_CR152","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig A-M, Kaech SM, Wherry EJ. CD8+ T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231\u201353.","journal-title":"Immunity"},{"issue":"1","key":"715_CR153","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37(1):457\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"715_CR154","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209\u201323.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"715_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104717","volume":"25","author":"JM Schafer","year":"2022","unstructured":"Schafer JM, Xiao T, Kwon H, Collier K, Chang Y, Abdel-Hafiz H, et al. Sex-biased adaptive immune regulation in cancer development and therapy. iScience. 2022;25(8): 104717.","journal-title":"iScience"},{"issue":"5","key":"715_CR156","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41568-024-00680-z","volume":"24","author":"T Xiao","year":"2024","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer. 2024;24(5):338\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"715_CR157","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0039-128X(02)00055-7","volume":"67","author":"WPM Benten","year":"2002","unstructured":"Benten WPM, Becker A, Schmitt-Wrede H-P, Wunderlich F. Developmental regulation of intracellular and surface androgen receptors in T cells. Steroids. 2002;67(11):925\u201331.","journal-title":"Steroids"},{"issue":"7915","key":"715_CR158","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606(7915):791\u20136.","journal-title":"Nature"},{"issue":"6","key":"715_CR159","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/0008-5472.CAN-22-2405","volume":"83","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cheng L, Gao C, Chen J, Liao S, Zheng Y, et al. Androgen signaling contributes to sex differences in cancer by inhibiting NF-\u03baB activation in T cells and suppressing antitumor immunity. Can Res. 2023;83(6):906\u201321.","journal-title":"Can Res"},{"issue":"1","key":"715_CR160","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","volume":"11","author":"Y Ye","year":"2020","unstructured":"Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11(1):1779.","journal-title":"Nat Commun"},{"issue":"6","key":"715_CR161","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737\u201346.","journal-title":"Lancet Oncol"},{"issue":"59","key":"715_CR162","doi-asserted-by":"publisher","first-page":"99336","DOI":"10.18632\/oncotarget.22242","volume":"8","author":"A Botticelli","year":"2017","unstructured":"Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget. 2017;8(59):99336.","journal-title":"Oncotarget"},{"issue":"12","key":"715_CR163","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/jcm7120542","volume":"7","author":"A Grassadonia","year":"2018","unstructured":"Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, et al. Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical trials. J Clin Med. 2018;7(12):542.","journal-title":"J Clin Med"},{"issue":"12","key":"715_CR164","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54(12):2701\u201311. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.015.","journal-title":"Immunity"},{"issue":"7","key":"715_CR165","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181(7):1612\u201325.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017.","journal-title":"Cell"},{"key":"715_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.945762","volume":"13","author":"KC Dodd","year":"2022","unstructured":"Dodd KC, Menon M. Sex bias in lymphocytes: implications for autoimmune diseases. Front Immunol. 2022;13: 945762. https:\/\/doi.org\/10.3389\/fimmu.2022.945762.","journal-title":"Front Immunol"},{"issue":"5","key":"715_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1645","volume":"16","author":"PJ Layug","year":"2024","unstructured":"Layug PJ, Vats H, Kannan K, Arsenio J. Sex differences in CD8+ T cell responses during adaptive immunity. WIREs Mech Dis. 2024;16(5): e1645. https:\/\/doi.org\/10.1002\/wsbm.1645.","journal-title":"WIREs Mech Dis"},{"issue":"11","key":"715_CR168","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discovery. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discovery"},{"issue":"16","key":"715_CR169","first-page":"1163","volume":"43","author":"X Yu","year":"2024","unstructured":"Yu X, Li C, Wang Z, Xu Y, Shao S, Shao F, et al. Neutrophils in cancer: dual roles through intercellular interactions. Oncogene. 2024;43(16):1163\u201377.","journal-title":"Oncogene"},{"issue":"4","key":"715_CR170","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49(4):595\u2013613.","journal-title":"Immunity"},{"issue":"4","key":"715_CR171","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MOH.0000000000000716","volume":"29","author":"A Y\u00e1\u00f1ez","year":"2022","unstructured":"Y\u00e1\u00f1ez A, Bono C, Goodridge HS. Heterogeneity and origins of myeloid cells. Curr Opin Hematol. 2022;29(4):201\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"715_CR172","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"715_CR173","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220011","volume":"219","author":"DF Quail","year":"2022","unstructured":"Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, et al. Neutrophil phenotypes and functions in cancer: a consensus statement. J Exp Med. 2022;219(6): e20220011.","journal-title":"J Exp Med"},{"issue":"1","key":"715_CR174","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1038\/s41467-019-12348-6","volume":"10","author":"ST Gal-Oz","year":"2019","unstructured":"Gal-Oz ST, Maier B, Yoshida H, Seddu K, Elbaz N, Czysz C, et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun. 2019;10(1):4295.","journal-title":"Nat Commun"},{"issue":"28","key":"715_CR175","doi-asserted-by":"publisher","first-page":"16481","DOI":"10.1073\/pnas.2003603117","volume":"117","author":"S Gupta","year":"2020","unstructured":"Gupta S, Nakabo S, Blanco LP, O\u2019Neil LJ, Wigerblad G, Goel RR, et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. Proc Natl Acad Sci. 2020;117(28):16481\u201391.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"715_CR176","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875\u201384.","journal-title":"Immunity"},{"issue":"1","key":"715_CR177","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954829","volume":"4","author":"O Draghiciu","year":"2015","unstructured":"Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells\u2014an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology. 2015;4(1): e954829.","journal-title":"Oncoimmunology"},{"issue":"9","key":"715_CR178","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Investig. 2015;125(9):3356\u201364.","journal-title":"J Clin Investig"},{"issue":"24","key":"715_CR179","doi-asserted-by":"publisher","first-page":"38378","DOI":"10.18632\/oncotarget.16386","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378.","journal-title":"Oncotarget"},{"issue":"15","key":"715_CR180","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1038\/onc.2016.367","volume":"36","author":"H Zhang","year":"2017","unstructured":"Zhang H, Ye Y, Li M, Ye S, Huang W, Cai T, et al. CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2017;36(15):2095\u2013104.","journal-title":"Oncogene"},{"key":"715_CR181","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","volume":"11","author":"A Hou","year":"2020","unstructured":"Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front Immunol. 2020;11:783.","journal-title":"Front Immunol"},{"issue":"23","key":"715_CR182","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","volume":"22","author":"M Sade-Feldman","year":"2016","unstructured":"Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+CD11b+HLA-DR\u2212 myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res. 2016;22(23):5661\u201372.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"715_CR183","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3892\/or.2012.1812","volume":"28","author":"S Ohki","year":"2012","unstructured":"Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep. 2012;28(2):453\u20138.","journal-title":"Oncol Rep"},{"key":"715_CR184","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","volume":"2","author":"SJ Santegoets","year":"2014","unstructured":"Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"715_CR185","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1038\/s41467-019-13571-x","volume":"10","author":"S Milette","year":"2019","unstructured":"Milette S, Hashimoto M, Perrino S, Qi S, Chen M, Ham B, et al. Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. Nat Commun. 2019;10(1):5745.","journal-title":"Nat Commun"},{"key":"715_CR186","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014: 149185. https:\/\/doi.org\/10.1155\/2014\/149185.","journal-title":"J Immunol Res"},{"issue":"9","key":"715_CR187","doi-asserted-by":"publisher","first-page":"14489","DOI":"10.1002\/jcp.28252","volume":"234","author":"P Shadpour","year":"2019","unstructured":"Shadpour P, Zamani M, Aghaalikhani N, Rashtchizadeh N. Inflammatory cytokines in bladder cancer. J Cell Physiol. 2019;234(9):14489\u201399. https:\/\/doi.org\/10.1002\/jcp.28252.","journal-title":"J Cell Physiol"},{"issue":"15","key":"715_CR188","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1073\/pnas.1424795112","volume":"112","author":"MT Cheah","year":"2015","unstructured":"Cheah MT, Chen JY, Sahoo D, Contreras-Trujillo H, Volkmer AK, Scheeren FA, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci USA. 2015;112(15):4725\u201330. https:\/\/doi.org\/10.1073\/pnas.1424795112.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"715_CR189","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/bjc.2011.262","volume":"105","author":"Z Adhim","year":"2011","unstructured":"Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer. 2011;105(3):393\u2013402. https:\/\/doi.org\/10.1038\/bjc.2011.262.","journal-title":"Br J Cancer"},{"issue":"5834","key":"715_CR190","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121\u20134. https:\/\/doi.org\/10.1126\/science.1140485.","journal-title":"Science"},{"issue":"3","key":"715_CR191","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cell.2005.12.032","volume":"124","author":"P Zhu","year":"2006","unstructured":"Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage\/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006;124(3):615\u201329. https:\/\/doi.org\/10.1016\/j.cell.2005.12.032.","journal-title":"Cell"},{"issue":"10","key":"715_CR192","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"715_CR193","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1878-0261.12397","volume":"13","author":"C Ibarra","year":"2019","unstructured":"Ibarra C, Karlsson M, Codeluppi S, Varas-Godoy M, Zhang S, Louhivuori L, et al. BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling. Mol Oncol. 2019;13(2):202\u201311. https:\/\/doi.org\/10.1002\/1878-0261.12397.","journal-title":"Mol Oncol"},{"issue":"2 Pt 1","key":"715_CR194","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/00005392-199508000-00072","volume":"154","author":"K Esuvaranathan","year":"1995","unstructured":"Esuvaranathan K, Alexandroff AB, McIntyre M, Jackson AM, Prescott S, Chisholm GD, James K. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 1995;154(2 Pt 1):572\u20135. https:\/\/doi.org\/10.1097\/00005392-199508000-00072.","journal-title":"J Urol"},{"issue":"4","key":"715_CR195","doi-asserted-by":"publisher","first-page":"101042831769755","DOI":"10.1177\/1010428317697552","volume":"39","author":"N Kumari","year":"2017","unstructured":"Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK, Saxena S. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumour Biol. 2017;39(4):1010428317697552. https:\/\/doi.org\/10.1177\/1010428317697552.","journal-title":"Tumour Biol"},{"issue":"6","key":"715_CR196","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/cam4.330","volume":"3","author":"BH Joshi","year":"2014","unstructured":"Joshi BH, Leland P, Lababidi S, Varrichio F, Puri RK. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med. 2014;3(6):1615\u201328. https:\/\/doi.org\/10.1002\/cam4.330.","journal-title":"Cancer Med"},{"issue":"10","key":"715_CR197","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/carcin\/18.10.1867","volume":"18","author":"K Hattori","year":"1997","unstructured":"Hattori K, Okamoto M, Oyasu R. Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma. Carcinogenesis. 1997;18(10):1867\u201370. https:\/\/doi.org\/10.1093\/carcin\/18.10.1867.","journal-title":"Carcinogenesis"},{"key":"715_CR198","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2020.06.018","volume":"490","author":"J Korac-Prlic","year":"2020","unstructured":"Korac-Prlic J, Degoricija M, Vilovic K, Haupt B, Ivanisevic T, Frankovic L, et al. Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model. Cancer Lett. 2020;490:89\u201399. https:\/\/doi.org\/10.1016\/j.canlet.2020.06.018.","journal-title":"Cancer Lett"},{"issue":"1","key":"715_CR199","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12885-019-5353-6","volume":"19","author":"CR Goulet","year":"2019","unstructured":"Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137. https:\/\/doi.org\/10.1186\/s12885-019-5353-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"715_CR200","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/(sici)1097-0215(19970703)72:1<149::aid-ijc21>3.0.co;2-d","volume":"72","author":"M Okamoto","year":"1997","unstructured":"Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997;72(1):149\u201354. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19970703)72:1%3c149::aid-ijc21%3e3.0.co;2-d.","journal-title":"Int J Cancer"},{"issue":"7","key":"715_CR201","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457\u201364. https:\/\/doi.org\/10.1084\/jem.20090207.","journal-title":"J Exp Med"},{"issue":"13","key":"715_CR202","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122998","volume":"5","author":"A Zychlinsky Scharff","year":"2019","unstructured":"Zychlinsky Scharff A, Rousseau M, Lacerda Mariano L, Canton T, Consiglio CR, Albert ML, et al. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection. JCI Insight. 2019;5(13): e122998. https:\/\/doi.org\/10.1172\/jci.insight.122998.","journal-title":"JCI Insight"},{"issue":"7","key":"715_CR203","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni1213","volume":"6","author":"GP Dunn","year":"2005","unstructured":"Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6(7):722\u20139. https:\/\/doi.org\/10.1038\/ni1213.","journal-title":"Nat Immunol"},{"issue":"10","key":"715_CR204","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","volume":"37","author":"JJ Duplisea","year":"2019","unstructured":"Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, et al. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2019;37(10):2041\u20139. https:\/\/doi.org\/10.1007\/s00345-018-2553-7.","journal-title":"World J Urol"},{"issue":"5","key":"715_CR205","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1577125","volume":"8","author":"D Plote","year":"2019","unstructured":"Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE III, Duplisea J, et al. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology. 2019;8(5): e1577125. https:\/\/doi.org\/10.1080\/2162402X.2019.1577125.","journal-title":"Oncoimmunology"},{"issue":"4","key":"715_CR206","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007808","volume":"12","author":"B Wang","year":"2024","unstructured":"Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T, et al. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. J Immunother Cancer. 2024;12(4): e007808. https:\/\/doi.org\/10.1136\/jitc-2023-007808.","journal-title":"J Immunother Cancer"},{"key":"715_CR207","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. https:\/\/doi.org\/10.3389\/fimmu.2018.00847.","journal-title":"Front Immunol"},{"issue":"1","key":"715_CR208","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","volume":"127","author":"J Riemensberger","year":"2002","unstructured":"Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol. 2002;127(1):20\u20136. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01734.x.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"715_CR209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271339","volume":"17","author":"C Gillezeau","year":"2022","unstructured":"Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, et al. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS ONE. 2022;17(8): e0271339. https:\/\/doi.org\/10.1371\/journal.pone.0271339.","journal-title":"PLoS ONE"},{"issue":"21","key":"715_CR210","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.3390\/cancers14215295","volume":"14","author":"SC Baker","year":"2022","unstructured":"Baker SC, Mason AS, Slip RG, Eriksson P, Sjodahl G, Trejdosiewicz LK, Southgate J. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers. 2022;14(21):5295. https:\/\/doi.org\/10.3390\/cancers14215295.","journal-title":"Cancers"},{"issue":"10","key":"715_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107937","volume":"26","author":"SL Freshour","year":"2023","unstructured":"Freshour SL, Chen TH, Fisk B, Shen H, Mosior M, Skidmore ZL, et al. Endothelial cells are a key target of IFN-g during response to combined PD-1\/CTLA-4 ICB treatment in a mouse model of bladder cancer. iScience. 2023;26(10): 107937. https:\/\/doi.org\/10.1016\/j.isci.2023.107937.","journal-title":"iScience"},{"issue":"6230","key":"715_CR212","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80\u20136. https:\/\/doi.org\/10.1126\/science.aaa4972.","journal-title":"Science"},{"issue":"2","key":"715_CR213","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrurol.2015.292","volume":"13","author":"M Alfano","year":"2016","unstructured":"Alfano M, Canducci F, Nebuloni M, Clementi M, Montorsi F, Salonia A. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol. 2016;13(2):77\u201390. https:\/\/doi.org\/10.1038\/nrurol.2015.292.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"715_CR214","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1038\/s41598-018-29054-w","volume":"8","author":"V Bucevic Popovic","year":"2018","unstructured":"Bucevic Popovic V, Situm M, Chow CT, Chan LS, Roje B, Terzic J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. https:\/\/doi.org\/10.1038\/s41598-018-29054-w.","journal-title":"Sci Rep"},{"issue":"1","key":"715_CR215","first-page":"57","volume":"2","author":"W Xu","year":"2014","unstructured":"Xu W, Yang L, Lee P, Huang WC, Nossa C, Ma Y, et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol. 2014;2(1):57\u201361.","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"715_CR216","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1099\/jmm.0.001058","volume":"68","author":"H Bi","year":"2019","unstructured":"Bi H, Tian Y, Song C, Li J, Liu T, Chen Z, et al. Urinary microbiota\u2014a potential biomarker and therapeutic target for bladder cancer. J Med Microbiol. 2019;68(10):1471\u20138. https:\/\/doi.org\/10.1099\/jmm.0.001058.","journal-title":"J Med Microbiol"},{"key":"715_CR217","doi-asserted-by":"publisher","first-page":"4824909","DOI":"10.1155\/2019\/4824909","volume":"2019","author":"G Mai","year":"2019","unstructured":"Mai G, Chen L, Li R, Liu Q, Zhang H, Ma Y. Common core bacterial biomarkers of bladder cancer based on multiple datasets. Biomed Res Int. 2019;2019:4824909. https:\/\/doi.org\/10.1155\/2019\/4824909.","journal-title":"Biomed Res Int"},{"key":"715_CR218","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejogrb.2017.04.040","volume":"214","author":"N Curtiss","year":"2017","unstructured":"Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. A case controlled study examining the bladder microbiome in women with overactive bladder (OAB) and healthy controls. Eur J Obstet Gynecol Reprod Biol. 2017;214:31\u20135. https:\/\/doi.org\/10.1016\/j.ejogrb.2017.04.040.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"715_CR219","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000475138","volume":"27","author":"Y Aso","year":"1995","unstructured":"Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol. 1995;27(2):104\u20139. https:\/\/doi.org\/10.1159\/000475138.","journal-title":"Eur Urol"},{"issue":"6","key":"715_CR220","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.euo.2020.04.002","volume":"3","author":"F Pederzoli","year":"2020","unstructured":"Pederzoli F, Ferrarese R, Amato V, Locatelli I, Alchera E, Luciano R, et al. Sex-specific alterations in the urinary and tissue microbiome in therapy-naive urothelial bladder cancer patients. Eur Urol Oncol. 2020;3(6):784\u20138. https:\/\/doi.org\/10.1016\/j.euo.2020.04.002.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"715_CR221","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/1751-2980.12595","volume":"19","author":"CP Kaur","year":"2018","unstructured":"Kaur CP, Vadivelu J, Chandramathi S. Impact of Klebsiella pneumoniae in lower gastrointestinal tract diseases. J Dig Dis. 2018;19(5):262\u201371. https:\/\/doi.org\/10.1111\/1751-2980.12595.","journal-title":"J Dig Dis"},{"issue":"1","key":"715_CR222","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12885-023-11383-3","volume":"23","author":"W Mingdong","year":"2023","unstructured":"Mingdong W, Xiang G, Yongjun Q, Mingshuai W, Hao P. Causal associations between gut microbiota and urological tumors: a two-sample mendelian randomization study. BMC Cancer. 2023;23(1):854. https:\/\/doi.org\/10.1186\/s12885-023-11383-3.","journal-title":"BMC Cancer"},{"issue":"8027","key":"715_CR223","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41586-024-07754-w","volume":"632","author":"B Roje","year":"2024","unstructured":"Roje B, Zhang B, Mastrorilli E, Kovacic A, Susak L, Ljubenkov I, et al. Gut microbiota carcinogen metabolism causes distal tissue tumours. Nature. 2024;632(8027):1137\u201344. https:\/\/doi.org\/10.1038\/s41586-024-07754-w.","journal-title":"Nature"},{"issue":"7","key":"715_CR224","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1021\/tx300132k","volume":"25","author":"S Rendic","year":"2012","unstructured":"Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol. 2012;25(7):1316\u201383. https:\/\/doi.org\/10.1021\/tx300132k.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"715_CR225","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1186\/s12885-018-5014-1","volume":"18","author":"T Zhou","year":"2018","unstructured":"Zhou T, Li HY, Xie WJ, Zhong Z, Zhong H, Lin ZJ. Association of glutathione S-transferase gene polymorphism with bladder cancer susceptibility. BMC Cancer. 2018;18(1):1088. https:\/\/doi.org\/10.1186\/s12885-018-5014-1.","journal-title":"BMC Cancer"},{"issue":"4","key":"715_CR226","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ijc.20157","volume":"110","author":"RJ Hung","year":"2004","unstructured":"Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110(4):598\u2013604. https:\/\/doi.org\/10.1002\/ijc.20157.","journal-title":"Int J Cancer"},{"issue":"1","key":"715_CR227","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1038\/s41598-021-85188-4","volume":"11","author":"YM Al-Saraireh","year":"2021","unstructured":"Al-Saraireh YM, Alshammari F, Youssef AMM, Al-Sarayreh S, Almuhaisen GH, Alnawaiseh N, et al. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021;11(1):5581. https:\/\/doi.org\/10.1038\/s41598-021-85188-4.","journal-title":"Sci Rep"},{"issue":"2","key":"715_CR228","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/dmd.112.046276","volume":"41","author":"SY Choi","year":"2013","unstructured":"Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41(2):263\u20139. https:\/\/doi.org\/10.1124\/dmd.112.046276.","journal-title":"Drug Metab Dispos"},{"key":"715_CR229","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2017.07.016","volume":"405","author":"C Stapelfeld","year":"2017","unstructured":"Stapelfeld C, Neumann KT, Maser E. Different inhibitory potential of sex hormones on NNK detoxification in vitro: a possible explanation for gender-specific lung cancer risk. Cancer Lett. 2017;405:120\u20136. https:\/\/doi.org\/10.1016\/j.canlet.2017.07.016.","journal-title":"Cancer Lett"},{"key":"715_CR230","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cbi.2017.02.016","volume":"276","author":"C Stapelfeld","year":"2017","unstructured":"Stapelfeld C, Maser E. Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases\/reductases and aldo-keto reductases in vitro. Chem Biol Interact. 2017;276:167\u201373. https:\/\/doi.org\/10.1016\/j.cbi.2017.02.016.","journal-title":"Chem Biol Interact"},{"issue":"11","key":"715_CR231","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1080\/15384047.2016.1235667","volume":"17","author":"E Kashiwagi","year":"2016","unstructured":"Kashiwagi E, Fujita K, Yamaguchi S, Fushimi H, Ide H, Inoue S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biol Ther. 2016;17(11):1188\u201396. https:\/\/doi.org\/10.1080\/15384047.2016.1235667.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"715_CR232","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2003.08.007","volume":"202","author":"L Zheng","year":"2003","unstructured":"Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett. 2003;202(1):61\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2003.08.007.","journal-title":"Cancer Lett"},{"issue":"2","key":"715_CR233","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","volume":"99","author":"R Meech","year":"2019","unstructured":"Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, et al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev. 2019;99(2):1153\u2013222. https:\/\/doi.org\/10.1152\/physrev.00058.2017.","journal-title":"Physiol Rev"},{"issue":"7","key":"715_CR234","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1158\/0008-5472.CAN-12-2388","volume":"73","author":"M Garcia-Closas","year":"2013","unstructured":"Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013;73(7):2211\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2388.","journal-title":"Cancer Res"},{"issue":"12","key":"715_CR235","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1124\/dmd.110.035345","volume":"38","author":"CJ Gallagher","year":"2010","unstructured":"Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos. 2010;38(12):2204\u20139. https:\/\/doi.org\/10.1124\/dmd.110.035345.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"715_CR236","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mc.21833","volume":"52","author":"K Izumi","year":"2013","unstructured":"Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog. 2013;52(2):94\u2013102. https:\/\/doi.org\/10.1002\/mc.21833.","journal-title":"Mol Carcinog"},{"issue":"30","key":"715_CR237","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1038\/sj.onc.1210229","volume":"26","author":"K Takayama","year":"2007","unstructured":"Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene. 2007;26(30):4453\u201363. https:\/\/doi.org\/10.1038\/sj.onc.1210229.","journal-title":"Oncogene"},{"issue":"3","key":"715_CR238","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jb\/mvp169","volume":"147","author":"K Iida","year":"2010","unstructured":"Iida K, Mimura J, Itoh K, Ohyama C, Fujii-Kuriyama Y, Shimazui T, et al. Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice. J Biochem. 2010;147(3):353\u201360. https:\/\/doi.org\/10.1093\/jb\/mvp169.","journal-title":"J Biochem"},{"issue":"4","key":"715_CR239","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/mc.21978","volume":"53","author":"K Izumi","year":"2014","unstructured":"Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, Netto GJ, Miyamoto H. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinog. 2014;53(4):314\u201324. https:\/\/doi.org\/10.1002\/mc.21978.","journal-title":"Mol Carcinog"},{"issue":"9","key":"715_CR240","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1042\/CS20160485","volume":"131","author":"R Ventura-Clapier","year":"2017","unstructured":"Ventura-Clapier R, Moulin M, Piquereau J, Lemaire C, Mericskay M, Veksler V, Garnier A. Mitochondria: a central target for sex differences in pathologies. Clin Sci. 2017;131(9):803\u201322. https:\/\/doi.org\/10.1042\/CS20160485.","journal-title":"Clin Sci"},{"issue":"1","key":"715_CR241","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13293-020-00291-x","volume":"11","author":"JB Rubin","year":"2020","unstructured":"Rubin JB, Lagas JS, Broestl L, Sponagel J, Rockwell N, Rhee G, et al. Sex differences in cancer mechanisms. Biol Sex Differ. 2020;11(1):17. https:\/\/doi.org\/10.1186\/s13293-020-00291-x.","journal-title":"Biol Sex Differ"},{"issue":"1","key":"715_CR242","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13293-024-00601-7","volume":"15","author":"B Jang","year":"2024","unstructured":"Jang B, Yoon D, Lee JY, Kim J, Hong J, Koo H, Sa JK. Integrative multi-omics characterization reveals sex differences in glioblastoma. Biol Sex Differ. 2024;15(1):23.","journal-title":"Biol Sex Differ"},{"issue":"8","key":"715_CR243","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","volume":"24","author":"K Vandereyken","year":"2023","unstructured":"Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023;24(8):494\u2013515.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"715_CR244","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41592-019-0692-4","volume":"17","author":"M Efremova","year":"2020","unstructured":"Efremova M, Teichmann SA. Computational methods for single-cell omics across modalities. Nat Methods. 2020;17(1):14\u20137.","journal-title":"Nat Methods"},{"issue":"10","key":"715_CR245","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24(10):695\u2013713.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"715_CR246","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41467-023-44570-8","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Duan M, Li J, Ma A, Xin G, Xu D, et al. MarsGT: multi-omics analysis for rare population inference using single-cell graph transformer. Nat Commun. 2024;15(1):338.","journal-title":"Nat Commun"},{"issue":"9","key":"715_CR247","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","volume":"18","author":"SM Lewis","year":"2021","unstructured":"Lewis SM, Asselin-Labat M-L, Nguyen Q, Berthelet J, Tan X, Wimmer VC, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods. 2021;18(9):997\u20131012.","journal-title":"Nat Methods"},{"issue":"9","key":"715_CR248","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Larsson L, Swarbrick A, Lundeberg J. Spatial landscapes of cancers: insights and opportunities. Nat Rev Clin Oncol. 2024;21(9):660\u201374.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"715_CR249","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792\u2013809.e23.","journal-title":"Cell"},{"issue":"6574","key":"715_CR250","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374(6574):abe6474.","journal-title":"Science"},{"issue":"6","key":"715_CR251","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29(6):1550\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"715_CR252","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12920-023-01535-6","volume":"16","author":"R Wu","year":"2023","unstructured":"Wu R, Teng X, Song Q, Chen S, Wang L, Liao J, Zou C. Single-cell RNA sequencing reveals sexual diversity in the human bladder and its prospective impacts on bladder cancer and urinary tract infection. BMC Med Genomics. 2023;16(1):122. https:\/\/doi.org\/10.1186\/s12920-023-01535-6.","journal-title":"BMC Med Genomics"},{"key":"715_CR253","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.euros.2021.05.002","volume":"29","author":"S Chenard","year":"2021","unstructured":"Chenard S, Jackson C, Vidotto T, Chen L, Hardy C, Jamaspishvilli T, et al. Sexual dimorphism in outcomes of non-muscle-invasive bladder cancer: a role of CD163+ macrophages, B cells, and PD-L1 immune checkpoint. Eur Urol Open Sci. 2021;29:50\u20138. https:\/\/doi.org\/10.1016\/j.euros.2021.05.002.","journal-title":"Eur Urol Open Sci"},{"issue":"12","key":"715_CR254","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00262-019-02423-8","volume":"68","author":"A Vidyarthi","year":"2019","unstructured":"Vidyarthi A, Agnihotri T, Khan N, Singh S, Tewari MK, Radotra BD, et al. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. Cancer Immunol Immunother. 2019;68(12):1995\u20132004. https:\/\/doi.org\/10.1007\/s00262-019-02423-8.","journal-title":"Cancer Immunol Immunother"},{"key":"715_CR255","doi-asserted-by":"publisher","first-page":"1009014","DOI":"10.3389\/fonc.2022.1009014","volume":"12","author":"B Duggan","year":"2022","unstructured":"Duggan B, O\u2019Rourke D, Anderson N, Reid CN, Watt J, O\u2019Kane H, et al. Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. Front Oncol. 2022;12:1009014.","journal-title":"Front Oncol"},{"issue":"5","key":"715_CR256","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-022-00466-x","volume":"23","author":"Q Ma","year":"2022","unstructured":"Ma Q, Xu D. Deep learning shapes single-cell data analysis. Nat Rev Mol Cell Biol. 2022;23(5):303\u20134.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"715_CR257","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41467-023-36559-0","volume":"14","author":"A Ma","year":"2023","unstructured":"Ma A, Wang X, Li J, Wang C, Xiao T, Liu Y, et al. Single-cell biological network inference using a heterogeneous graph transformer. Nat Commun. 2023;14(1):964.","journal-title":"Nat Commun"},{"issue":"1","key":"715_CR258","first-page":"7467","volume":"15","author":"Y Chang","year":"2024","unstructured":"Chang Y, Liu J, Jiang Y, Ma A, Yeo YY, Guo Q, et al. Graph Fourier transform for spatial omics representation and analyses of complex organs. Res Sq. 2024;15(1):7467.","journal-title":"Res Sq"},{"issue":"12","key":"715_CR259","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41551-022-00942-x","volume":"6","author":"MM Li","year":"2022","unstructured":"Li MM, Huang K, Zitnik M. Graph representation learning in biomedicine and healthcare. Nat Biomed Eng. 2022;6(12):1353\u201369.","journal-title":"Nat Biomed Eng"},{"issue":"7947","key":"715_CR260","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/d41586-023-00340-6","volume":"614","author":"C Stokel-Walker","year":"2023","unstructured":"Stokel-Walker C, Van Noorden R. What ChatGPT and generative AI mean for science. Nature. 2023;614(7947):214\u20136.","journal-title":"Nature"},{"issue":"7972","key":"715_CR261","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41586-023-06221-2","volume":"620","author":"H Wang","year":"2023","unstructured":"Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. Nature. 2023;620(7972):47\u201360.","journal-title":"Nature"},{"issue":"8","key":"715_CR262","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41580-024-00756-6","volume":"25","author":"Q Ma","year":"2024","unstructured":"Ma Q, Jiang Y, Cheng H, Xu D. Harnessing the deep learning power of foundation models in single-cell omics. Nat Rev Mol Cell Biol. 2024;25(8):593\u20134.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"715_CR263","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41592-024-02201-0","volume":"21","author":"H Cui","year":"2024","unstructured":"Cui H, Wang C, Maan H, Pang K, Luo F, Duan N, Wang B. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat Methods. 2024;21(8):1470\u201380.","journal-title":"Nat Methods"},{"issue":"8","key":"715_CR264","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/s41592-024-02305-7","volume":"21","author":"M Hao","year":"2024","unstructured":"Hao M, Gong J, Zeng X, Liu C, Guo Y, Cheng X, et al. Large-scale foundation model on single-cell transcriptomics. Nat Methods. 2024;21(8):1481\u201391.","journal-title":"Nat Methods"},{"issue":"7965","key":"715_CR265","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","volume":"618","author":"CV Theodoris","year":"2023","unstructured":"Theodoris CV, Xiao L, Chopra A, Chaffin MD, Al Sayed ZR, Hill MC, et al. Transfer learning enables predictions in network biology. Nature. 2023;618(7965):616\u201324.","journal-title":"Nature"},{"issue":"8015","key":"715_CR266","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-024-07441-w","volume":"630","author":"H Xu","year":"2024","unstructured":"Xu H, Usuyama N, Bagga J, Zhang S, Rao R, Naumann T, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181\u20138.","journal-title":"Nature"},{"issue":"8","key":"715_CR267","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ccell.2022.07.004","volume":"40","author":"RJ Chen","year":"2022","unstructured":"Chen RJ, Lu MY, Williamson DF, Chen TY, Lipkova J, Noor Z, et al. Pan-cancer integrative histology-genomic analysis via multimodal deep learning. Cancer Cell. 2022;40(8):865\u201378.e6.","journal-title":"Cancer Cell"},{"issue":"6","key":"715_CR268","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41568-024-00694-7","volume":"24","author":"R Perez-Lopez","year":"2024","unstructured":"Perez-Lopez R, Ghaffari Laleh N, Mahmood F, Kather JN. A guide to artificial intelligence for cancer researchers. Nat Rev Cancer. 2024;24(6):427\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"715_CR269","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jnci\/djab028","volume":"113","author":"SS Jackson","year":"2021","unstructured":"Jackson SS, Han X, Mao Z, Nogueira L, Suneja G, Jemal A, Shiels MS. Cancer stage, treatment, and survival among transgender patients in the United States. J Natl Cancer Inst. 2021;113(9):1221\u20137. https:\/\/doi.org\/10.1093\/jnci\/djab028.","journal-title":"J Natl Cancer Inst"}],"container-title":["Biology of Sex Differences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-025-00715-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13293-025-00715-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-025-00715-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T21:01:19Z","timestamp":1748811679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bsd.biomedcentral.com\/articles\/10.1186\/s13293-025-00715-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":269,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1186\/s13293-025-00715-6","relation":{},"ISSN":["2042-6410"],"issn-type":[{"value":"2042-6410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}